ArticleExperimental hematology & oncology2014
Ibrutinib for B cell malignancies.
Article in Experimental hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 76 citations in OpenAlex.
- Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.Blood advances · 2026Article
- Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy.The oncologist · 2025Article
- Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.Journal of molecular and cellular cardiology · 2024Review
- Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?Cancers · 2024Review
- New developments in Aspergillus fumigatus and host reactive oxygen species responses.Current opinion in microbiology · 2024Review
- B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.Scientific reports · 2024Article
- A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-Acta pharmaceutica Sinica. B · 2023Article
- Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.Cells · 2022Review
- Unusual cause of light chain cast nephropathy.BMJ case reports · 2022Article
- Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database.Frontiers in pharmacology · 2022Article
- Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib.Cureus · 2021Article
- The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View.Journal of experimental pharmacology · 2021Review
- The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Review
- Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.Cancers · 2020Article
- p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2019Article
- Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.Blood cancer journal · 2019Review
- Covalent Inhibition in Drug Discovery.ChemMedChem · 2019Review
- Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression.Biomedicines · 2018Review
- Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research over the role of Bruton's agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765), a potent inhibitor of BTK induces impressive responses in B-cell malignancies through irreversible bond with cysteine-481 in the active site of BTK (TH/SH1 domain) and inhibits BTK phosphorylation on Tyr223. This review discussed in details the role of BTK in B-cell signaling, molecular interactions between B cell lymphoma/leukemia cells and their microenvironment. Clinical trials of the novel BTK inhibitor, ibrutinib (PCI-32765), in B cell malignancies were summarized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.